Tech Company Financing Transactions
Kymera Therapeutics Funding Round
Atlas Venture, Amgen Ventures and Lilly Ventures joined a $30 million Series A funding round for Kymera Therapeutics. This venture round was announced on 10/31/2017.
Transaction Overview
Company Name
Announced On
10/31/2017
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The company is pioneering a novel targeted protein degradation platform and approach to accelerate drug discovery and development, and deliver on its mission.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
300 Technology Sq. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Kymera Therapeutics (Nasdaq: KYMR). Despite recent advances in modern medicine, hundreds of millions of people are affected by acute and chronic diseases with limited or no available treatment options. Kymera is pioneering a game-changing new therapeutic modality with the potential to transform drug discovery and provide breakthrough treatments for previously untreatable diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nello Mainolfi
Chief Financial Officer
Bruce Jacobs
Chief Medical Officer
Jared Gollob
Browse more venture capital transactions:
Prev: 10/31/2017: Waycare venture capital transaction
Next: 10/31/2017: Ada Health venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs